After a lengthy gestation of a few years whilst new trial data became available, ABCD is, at last, pleased to announce a Position Statement on the Cardiovascular Impact of New Diabetes Medications – DPP-IV inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors.

This is the second of our 2021 ABCD webinar series which run on the first Thursday of each month.

E. Wilmot, H. Deshmukh, R. Gregory, A. Kilvert, D. Barnes, R. Herring, R. Banatwalla, P. Narendran, J. Patmore, C. Walton, T. Sathyapalan, R. Ryder

H. Deshmukh, E. Wilmot, R. Gregory, A. Kilvert, D. Barnes, R. Herring, R. Banatwalla, P. Narendran, J. Patmore, C. Walton, R. Ryder, T. Sathyapalan

TSJ Crabtree^1-3, A Lumb⁴, P Hammond⁵, P Choudhary⁶, REJ Ryder³, A McLay⁷, EG Wilmot^1,2

Crabtree TSJ, Winnocour P, Darzy K; Phillips S, Sennik D, Rohilla A, Raghavan R, Evans A, Bickerton A, I Gallen, Yadigiri M, Ryder REJ on behalf of the ABCD Canagliflozin Audit Contributors

Zafar M, Randhawa R S, Hegner J, Alam S, Farooq M, Eldebri R, Barry L, Pun B, Shahbaz M, Makanjuola O A, Cuison F, Safarova D, Lawrence K, Elyasaky A, Nooredinvand H A, Periasamy M, Khanna A, Subba K, Adekunle B A, Ojofeitimi O, Morete Esteves A, Ciroi T M G, Moran S, O’Neill W, Taylor N, Muhammad T, Dashora U

East Sussex Healthcare NHS Trust

Yates P, Nazir-Salim K, Rowles Dr S

Pennine Acute Hospitals trust, Part of the Northern Care Alliance.